Dr. Cheng is the Founder and President of AllSaf Clinical Research, Inc.  He holds both an M.D. and a Ph.D. Over the course of his career, he has held executive leadership roles, including President, Chief Executive Officer (CEO), Chief Medical Officer (CMO), Chief Scientific Officer (CSO), Director, and Senior Vice President (SVP) of Translational Medicine, across organizations ranging from startups to S&P 100 enterprise. His leadership experience spans the pharmaceutical, biotechnology, and clinical research (CRO) sectors. 

Prior to his industry career, Dr. Cheng held a faculty position specializing in immunomodulation, immune tolerance induction for organ transplantation at University of Maryland and was actively involved in cancer research at the same university. With over 25 years of experience, his expertise spans clinical research, drug development, R&D, preclinical study and translational medicine in various areas, including drug development lifecycle management, cancers, vaccines, neurology, immunotherapy, cell therapy, gene therapy, organ transplantation, stem cell, anti-aging, cardiovascular diseases, immunology, immunomodulation, biochemistry, cell and molecule biology. Dr. Cheng has authored more than 90 publications.

Dr. Cheng specialized in postdoctoral research in Biochemistry and Molecular Biology at Northwestern University, Chicago, USA, under the mentorship of a member of the U.S. National Academy of Sciences (NAS).